Howard West
Medical Oncology · Duarte, CANPI 1346324068
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $279,154 of the $426,332 with a category attached, or 65.5%. 32 manufacturers reported payments, led by Merck at 28.3% of the total. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 271 payments — averaging $1573.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$121K
- AstraZeneca$110K
- Takeda Pharmaceuticals U.S.A., Inc.$38K
- Eli Lilly$18K
- Bristol Myers Squibb$15K
- Amgen$15K
- plus $110K from 26 others
Across 49 payments — averaging $2051.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Clovis Oncology, Inc.$29K
- Takeda Pharmaceuticals U.S.A., Inc.$23K
- Taiho Oncology, Inc.$18K
- F. Hoffmann-la Roche AG$14K
- Genentech, Inc.$10K
- Bristol Myers Squibb$5K
- plus $1K from 3 others
What the payments were for
- Consulting fees$279,15465%
- Speaking & faculty fees$117,17627%
- Travel & lodging$26,0866%
- Food & beverage$3,8401%
- Education$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 40 | $120,628 |
| AstraZeneca | 82 | $110,242 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $38,019 |
| Eli Lilly | 5 | $17,525 |
| Bristol Myers Squibb | 13 | $15,290 |
| Amgen | 6 | $14,988 |
| Ipsen Biopharmaceuticals, Inc | 17 | $13,079 |
| F. Hoffmann-la Roche AG | 11 | $11,286 |
| Genentech USA, Inc. | 5 | $10,627 |
| Jazz Pharmaceuticals Inc. | 3 | $8,225 |
| Hoffmann-la Roche Limited | 4 | $8,057 |
| Gyrus ACMI, Inc. | 3 | $6,360 |
| GSK | 2 | $5,431 |
| Coherus Oncology, Inc. | 8 | $5,165 |
| Incyte Corporation | 6 | $5,002 |
| Gilead | 5 | $4,455 |
| Daiichi Sankyo Inc. | 2 | $4,213 |
| Janssen Scientific Affairs, LLC | 4 | $4,040 |
| AbbVie | 3 | $3,300 |
| Genentech, Inc. | 3 | $3,065 |
| Boehringer Ingelheim | 3 | $2,600 |
| Novocure GmbH | 1 | $2,400 |
| Mirati Therapeutics, Inc. | 4 | $2,079 |
| Regeneron | 3 | $1,965 |
| Eisai Inc. | 1 | $1,875 |
| Astrazeneca UK Limited | 2 | $1,730 |
| Lilly USA, LLC | 1 | $1,400 |
| Exelixis Inc. | 2 | $1,320 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,159 |
| Novocure Inc. | 1 | $500 |
| Seagen Inc. | 1 | $288 |
| Johnson & Johnson | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$426,332 in reported general payments places this provider in the 95th percentile of 379 medical oncology providers in California.
Other medical oncology in Duarte
- Daneng LiDuarte$467K
- Christine LovlyDuarte$362K
- Marwan FakihDuarte$203K
- Erminia MassarelliDuarte$176K
- Ravi SalgiaDuarte$142K
- Tanya DorffDuarte$136K
- Karen ReckampDuarte$132K
- Cy SteinDuarte$122K
- Joseph ChaoDuarte$110K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.